Abstract
The effect of cholecalciferol (25OHD) therapy on parathormone levels (PTH) have been well studied in CKD. However, the endocrine effect of daily vs weekly or monthly treatment regimens of 25OHD supplementation on biomarkers of bone formation and resorption are not known. We investigated the effect of 25OHD supplementation on the bone biomarkers (Bone alkaline phosphatase (BAP), tartrate resistant acid phosphatase (TRAP), C terminal telopeptide of type 1 collagen (CTX), N terminal propeptide of type 1 procollagen (PINP), sclerostin) in children with CKD stages 2-4.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
